ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Brokerages

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average rating of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $105.00.

Several equities analysts have recently commented on the stock. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Canaccord Genuity Group began coverage on ANI Pharmaceuticals in a report on Thursday, July 16th. They set a “hold” rating and a $91.00 price target on the stock. Guggenheim reaffirmed a “buy” rating and set a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Finally, Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th.

Insider Activity

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. The trade was a 20.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. The trade was a 4.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 85,179 shares of company stock valued at $6,722,596. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. KBC Group NV bought a new position in ANI Pharmaceuticals in the first quarter worth about $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. Hantz Financial Services Inc. boosted its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.9%

Shares of NASDAQ ANIP opened at $81.78 on Friday. The firm’s fifty day moving average is $81.25 and its 200 day moving average is $79.49. ANI Pharmaceuticals has a 52 week low of $62.60 and a 52 week high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 20.70 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts expect that ANI Pharmaceuticals will post 8.03 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.